Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
polyvalent melanoma vaccine
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Immunotherapy With Polyvalent Melanoma Vaccine (Canvaxin™) Plus BCG Versus BCG Plus Placebo After Surgery in Patients With Stage IV Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
18 to 80
Sponsor:
NCI
Protocol IDs:
JWCI-MC-4-001
, CV-MMAIT-4-001, RPCI-DS-98-16, NCI-G98-1492, NCT00052156
2.
Phase III Randomized Study of BCG Plus a Polyvalent Melanoma Vaccine (Canvaxin™) Versus BCG Plus Placebo in Patients With Resected Stage III Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
18 to 80
Sponsor:
NCI
Protocol IDs:
JWCI-MC-3-001A
, CV-MMAIT-3-001, NCI-V99-1576, NCT00052130
3.
Phase II Randomized Study of Polyvalent Melanoma Vaccine Encapsulated into pH-Sensitive Liposomes in Patients with Stage IIB or III Malignant Melanoma (Summary Last Modified 03/2000)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
NYU-9615
, NCI-G98-1488
4.
Phase II Randomized Study of Polyvalent Melanoma Vaccine and Interleukin-2 Liposome With or Without One of Two Doses of Interferon alfa-2b in Patients With Stage III Malignant Melanoma (Summary Last Modified 08/2001)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
NYU-9837
, NCI-G99-1595, NCT00004104
5.
Phase II Study of Polyvalent Melanoma Vaccine (Canvaxin™) in Patients With In-Transit Cutaneous Malignant Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 to 80
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CV-MMAIT-5-001
, NCT00128583
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute